ANI Pharmaceuticals Inc. (ANIP) Downgraded by Zacks Investment Research to “Hold”
According to Zacks, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. “
Several other brokerages have also recently weighed in on ANIP. Raymond James Financial Inc. assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, June 22nd. They set a strong-buy rating and a $68.00 price target on the stock. Citigroup Inc. lowered ANI Pharmaceuticals from an outperform rating to a market perform rating and set a $49.00 price objective for the company. in a report on Friday, July 8th. They noted that the move was a valuation call. TheStreet raised ANI Pharmaceuticals from a hold rating to a buy rating in a report on Friday, August 26th. Guggenheim reissued a buy rating and set a $80.00 price objective (up previously from $65.00) on shares of ANI Pharmaceuticals in a report on Friday, August 5th. Finally, Oppenheimer Holdings Inc. boosted their price objective on ANI Pharmaceuticals from $65.00 to $71.00 and gave the stock an outperform rating in a report on Friday, August 5th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. ANI Pharmaceuticals presently has a consensus rating of Buy and an average target price of $64.00.
ANI Pharmaceuticals (NASDAQ:ANIP) traded down 0.55% on Wednesday, reaching $68.58. 29,624 shares of the company’s stock traded hands. ANI Pharmaceuticals has a 12 month low of $26.80 and a 12 month high of $70.92. The firm’s 50-day moving average is $64.50 and its 200 day moving average is $54.54. The firm has a market cap of $789.63 million, a PE ratio of 80.59 and a beta of 2.92.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.34. ANI Pharmaceuticals had a return on equity of 20.12% and a net margin of 11.02%. The firm had revenue of $31.30 million for the quarter, compared to analysts’ expectations of $27.63 million. During the same period in the prior year, the business posted $0.55 earnings per share. The company’s revenue was up 60.5% on a year-over-year basis. Equities analysts predict that ANI Pharmaceuticals will post $4.12 EPS for the current year.
In other ANI Pharmaceuticals news, insider Arthur Przybyl sold 37,455 shares of the business’s stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $66.97, for a total value of $2,508,361.35. Following the completion of the sale, the insider now owns 200,788 shares in the company, valued at $13,446,772.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert W. Schrepfer sold 12,500 shares of the business’s stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $67.06, for a total value of $838,250.00. Following the completion of the sale, the vice president now owns 17,362 shares of the company’s stock, valued at approximately $1,164,295.72. The disclosure for this sale can be found here. 31.60% of the stock is owned by company insiders.
A number of hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA increased its stake in shares of ANI Pharmaceuticals by 94.9% in the second quarter. BNP Paribas Arbitrage SA now owns 2,364 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 1,151 shares during the last quarter. Bank of Montreal Can bought a new stake in shares of ANI Pharmaceuticals during the second quarter valued at $177,000. Thrivent Financial for Lutherans bought a new stake in shares of ANI Pharmaceuticals during the second quarter valued at $204,000. Arizona State Retirement System bought a new stake in shares of ANI Pharmaceuticals during the second quarter valued at $219,000. Finally, BlackRock Advisors LLC increased its stake in shares of ANI Pharmaceuticals by 6.1% in the second quarter. BlackRock Advisors LLC now owns 3,975 shares of the specialty pharmaceutical company’s stock valued at $222,000 after buying an additional 230 shares during the last quarter. Hedge funds and other institutional investors own 48.74% of the company’s stock.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.